Randomized, Double-Blind, Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer
Randomized, Double-Blind, Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer
The purpose of this study is to determine if asymptomatic or minimally symptomatic patients with metastatic prostate cancer who have not received chemotherapy live longer when treated with ipilimumab than those treated with a placebo
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Buenos Aires, Buenos Aires 1120, Argentina
Buenos Aires, Buenos Aires C1280AEB, Argentina
Buenos Aires, Buenos Aires C1426BOS, Argentina
East Bentleigh, Victoria 3165, Australia
Belo Horizonte - Mg, Minas Gerais 31150, Brazil
Sittard-geleen, 6162 BG, Netherlands
Bornova, Izmir, 35100, Turkey (Türkiye)